Short interest for Inoviq gives investors a sense of the degree to which investors are betting on the decline of Inoviq's stock. Short interest data is updated every two weeks.

Inoviq Stock Short Interest Report | OTC:BDLSF | Benzinga

Inoviq

Overview

Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. The Group operates predominantly in one business segment, the research and development of cancer diagnostics, and two geographical segments, Victoria, Australia, and the United States of America, with the majority of revenue coming from Australia.

Comments

Inoviq Short Interest Report

Inoviq Stock Short Interest Report | OTC:BDLSF | Benzinga